BRPI0509540A - uso de agonistas do receptor delta ativado pelo proliferador de peroxissoma para o tratamento de ms e outras doenças desmielinizantes - Google Patents

uso de agonistas do receptor delta ativado pelo proliferador de peroxissoma para o tratamento de ms e outras doenças desmielinizantes

Info

Publication number
BRPI0509540A
BRPI0509540A BRPI0509540-9A BRPI0509540A BRPI0509540A BR PI0509540 A BRPI0509540 A BR PI0509540A BR PI0509540 A BRPI0509540 A BR PI0509540A BR PI0509540 A BRPI0509540 A BR PI0509540A
Authority
BR
Brazil
Prior art keywords
demyelinating diseases
treatment
receptor agonists
delta receptor
peroxisome proliferator
Prior art date
Application number
BRPI0509540-9A
Other languages
English (en)
Portuguese (pt)
Inventor
Karen Chandross
Jean Merrill
Anne Minnich
Lan Lee
Olga Khorkova
Yun Liu
Original Assignee
Aventis Pharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aventis Pharma Inc filed Critical Aventis Pharma Inc
Publication of BRPI0509540A publication Critical patent/BRPI0509540A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/426—1,3-Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
BRPI0509540-9A 2004-04-01 2005-03-29 uso de agonistas do receptor delta ativado pelo proliferador de peroxissoma para o tratamento de ms e outras doenças desmielinizantes BRPI0509540A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US55853304P 2004-04-01 2004-04-01
PCT/US2005/010371 WO2005097098A2 (en) 2004-04-01 2005-03-29 Use of ppr delta agonists for treating demyelinating diseases

Publications (1)

Publication Number Publication Date
BRPI0509540A true BRPI0509540A (pt) 2007-09-18

Family

ID=34977094

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0509540-9A BRPI0509540A (pt) 2004-04-01 2005-03-29 uso de agonistas do receptor delta ativado pelo proliferador de peroxissoma para o tratamento de ms e outras doenças desmielinizantes

Country Status (16)

Country Link
US (1) US20070149580A1 (https=)
EP (1) EP1737440A2 (https=)
JP (1) JP2007530703A (https=)
KR (1) KR20060134191A (https=)
CN (1) CN1950077A (https=)
AU (1) AU2005231358A1 (https=)
BR (1) BRPI0509540A (https=)
CA (1) CA2561159A1 (https=)
IL (1) IL178165A0 (https=)
MA (1) MA28561B1 (https=)
MX (1) MXPA06011218A (https=)
NO (1) NO20064985L (https=)
RU (1) RU2006138495A (https=)
SG (1) SG138623A1 (https=)
WO (1) WO2005097098A2 (https=)
ZA (1) ZA200607850B (https=)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE602005024384D1 (de) 2004-05-05 2010-12-09 High Point Pharmaceuticals Llc Neue verbindungen, ihre herstellung und verwendung
US8053598B2 (en) 2004-05-05 2011-11-08 High Point Pharmaceuticals, Llc Compounds, their preparation and use
ES2372617T3 (es) 2005-06-30 2012-01-24 High Point Pharmaceuticals, Llc Ácidos fenoxiacéticos como activadores de ppar-delta.
EP1964575B1 (en) * 2005-11-28 2015-09-23 Senju Pharmaceutical Co., Ltd. Pharmaceutical comprising ppar agonist
CN103224477A (zh) 2005-12-22 2013-07-31 高点制药有限责任公司 作为PPAR-δ活化剂的苯氧基乙酸
US7943612B2 (en) 2006-03-09 2011-05-17 High Point Pharmaceuticals, Llc Compounds that modulate PPAR activity, their preparation and use
US8716317B2 (en) 2008-06-09 2014-05-06 Sanofi Sulfonamides with heterocycle and oxadiazolone headgroup, processes for their preparation and their use as pharmaceuticals
US8329725B2 (en) 2008-06-09 2012-12-11 Sanofi Annelated pyrrolidin sulfonamides with oxadiazolone headgroup, processes for their preparation and their use as pharmaceuticals
EP2483406A2 (en) 2009-09-30 2012-08-08 President and Fellows of Harvard College Methods for modulation of autophagy through the modulation of autophagy-inhibiting gene products
KR20120107113A (ko) 2009-12-17 2012-09-28 사노피 수초 염기성 단백질 프로모터(ｍｂｐ-ｌｕｃｉ)의 조절 하에 루시페라제를 발현하는 동물 모델 및 생물발광 생체내 영상화를 위한 상기 동물 모델의 용도
JP6133790B2 (ja) * 2011-02-18 2017-05-24 ザ スクリプス リサーチ インスティテュート ミエリン形成細胞運命へのオリゴデンドロサイト前駆細胞の定方向分化
EP3756661A1 (en) 2013-09-09 2020-12-30 vTv Therapeutics LLC Use of a ppar-delta agonist for treating muscle atrophy
WO2021092279A1 (en) * 2019-11-06 2021-05-14 Board Of Regents, The University Of Texas System Methods for the treatment of dysmyelinating/demyelinating diseases
WO2023147309A1 (en) 2022-01-25 2023-08-03 Reneo Pharmaceuticals, Inc. Use of ppar-delta agonists in the treatment of disease

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU1856997A (en) * 1996-02-02 1997-08-22 Merck & Co., Inc. Method for raising hdl cholesterol levels
GB9914977D0 (en) * 1999-06-25 1999-08-25 Glaxo Group Ltd Chemical compounds
AU2001288271A1 (en) * 2000-08-17 2002-02-25 Harrihar A. Pershadsingh Methods for treating inflammatory diseases
GB0024362D0 (en) * 2000-10-05 2000-11-22 Glaxo Group Ltd Medicaments
GB0024361D0 (en) * 2000-10-05 2000-11-22 Glaxo Group Ltd Medicaments
WO2004082621A2 (en) * 2003-03-15 2004-09-30 Bethesda Pharmaceuticals, Inc. Novel ppar agonists, pharmaceutical compositions and uses thereof
JPWO2004093910A1 (ja) * 2003-04-22 2006-07-13 アステラス製薬株式会社 ＰＰＡＲδアゴニストによる脳神経変性疾患治療剤

Also Published As

Publication number Publication date
WO2005097098A2 (en) 2005-10-20
MXPA06011218A (es) 2007-01-16
CN1950077A (zh) 2007-04-18
KR20060134191A (ko) 2006-12-27
JP2007530703A (ja) 2007-11-01
ZA200607850B (en) 2008-10-29
IL178165A0 (en) 2008-03-20
EP1737440A2 (en) 2007-01-03
CA2561159A1 (en) 2005-10-20
NO20064985L (no) 2006-10-31
WO2005097098A3 (en) 2005-12-22
RU2006138495A (ru) 2008-05-10
US20070149580A1 (en) 2007-06-28
MA28561B1 (fr) 2007-04-03
SG138623A1 (en) 2008-01-28
AU2005231358A1 (en) 2005-10-20

Similar Documents

Publication Publication Date Title
BRPI0509540A (pt) uso de agonistas do receptor delta ativado pelo proliferador de peroxissoma para o tratamento de ms e outras doenças desmielinizantes
BRPI0514253A (pt) terapia de combinação para diabetes, obesidade e doenças cardiovasculares usando composições contendo inibidores de gdf-8
BRPI0909749A2 (pt) uso de fotoiniciador para fabrico de medicamento para tratamento do ceratocone, da ectasia e fortalecimento da córnea
BRPI0409364A (pt) processo para tratamento da doença de parkinson
BR112015001158A2 (pt) formulação oftálmica e respectivo uso e método para melhorar, reduzir ou tratar presbiopia
BR0112476A (pt) Uso de agonistas do receptor d2/d3 de dopamina para tratar fibromialgia
BR0309623A (pt) Agentes que regulam. inibem ou modulam a atividade e/ou a expressão do fator de crescimento de tecido conjuntivo (ctgf) como um único meio de diminuir a pressão intraocular e tratar retinopatias glaucomatosas/neuropatias ópticas
BR0116370A (pt) Composto, composição farmacêutica, uso de um composto, e, método de tratamento de uma doença ou condição mediada por hppar em um paciente.
BRPI0819081A8 (pt) Formulação oftálmica aquosa, processo para preparar a mesma, e, método para inibir, tratar ou prevenir doenças oculares e doença ou condição relacionada, em um paciente em necessidade de tal tratamento
BR0215029A (pt) Molécula de insulina, uso da mesma, composição, uso desta, microcristal, processo para prepará-lo, uso deste, e, métodos para preparar uma molécula de insulina, para tratar hiperglicemia, e para tratar diabetes mellitus
EA200900940A1 (ru) Фармацевтическая композиция, содержащая пиразол-о-глюкозидное производное
ATE549323T1 (de) Prophylaktisches und/oder therapeutisches mittel gegen hyperlipidemie
MA52861B1 (fr) Méthodes et compositions pour le traitement de l'apnée du sommeil ou le ronflement simple
EP4714494A3 (en) A myostatin pathway inhibitor in combination with a glp-1 pathway activator for use in treating metabolic disorders
BR112022018645A2 (pt) Composições e métodos para tratar ou prevenir doenças inflamatórias, incluindo diabetes mellitus tipo i e tipo ii e doenças da tireoide
BR112012006010A2 (pt) composto de glicina
EA201401231A1 (ru) Фармацевтические комбинации, предназначенные для лечения метаболических нарушений
WO2006108424A3 (en) Beta-2 adrenoceptor agonists for treating connective tissue diseases of the skin
MX2021005905A (es) Metodo seguro y eficaz para tratar la psoriasis con el anticuerpo especifico anti-il-23.
MY148866A (en) Use of benzo-fused heterocycle sulfamide derivatives for lowering lipids and lowering blood glucose levels
BRPI0411665A (pt) uso de agomelatina ou de um seu sal farmaceuticamente aceitável, composição farmacêutica ou kit, e, métodos para o tratamento de doenças ou distúrbios responsivos a um inibidor da recaptação de serotonina e para aumentar e/ou proporcionar inìcio mais rápido do efeito terapêutico de um inibidor da recaptação de serotonina
BR112012020185A2 (pt) uso de preparações de heparina oral para tratar doenças e afecções do trato urinário.
BR0310061A (pt) Métodos para o tratamento de doenças e condições respiratórias com um inibidor seletivo da inos e um inibidor da pde e suas composições
BR112017016267A2 (pt) processo terapêutico para tratar um olho para parar ou retardar o início ou sintomas de doenças de retina
BR112015027984A2 (pt) Agonistas alfa adrenérgicos para o tratamento de lesão de tecido

Legal Events

Date Code Title Description
B25G Requested change of headquarter approved

Owner name: AVENTIS PHARMACEUTICALS, INC. (US)

Free format text: SEDE ALTERADA CONFORME SOLICITADO NA PETICAO NO 020070165509/RJ DE 23/11/2007.

B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE AS 6A E 7A ANUIDADES.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2158 DE 15/05/2012.